Sabinsa Corporation announced today that it has successfully concluded its Patent Infringement lawsuit against Aegle Bios, Inc. A Final Consent Judgment was filed in the United States District Court in New Jersey on June 23, 2017.
On June 8, 2016, Sabinsa filed suit against Aegle for willful infringement of the Curcumin Patent No. 6,653,327. The ’327 Patent protects Sabinsa’s methods and formulations for Tetrahydrocurcuminoids (THCs).
The Final Consent Judgment stipulates that the ’327 Patent was valid, enforceable, and properly issued by the U.S. Patent and Trademark Office. Sabinsa has patents related to THCs in the United States, Europe, Australia, New Zealand, and other locations. In the United States, Sabinsa continues to litigate the amount owed for willful infringement of the ’327 patent by Olive Lifesciences Private Limited after obtaining final judgments against Chemill Inc. and Nachurel Ingredients LLC.
“As an pioneer in the industry, Sabinsa has researched and developed many innovative and successful products used by the nutritional supplement industry, but unfortunately that success has made us a target for IP theft,” said Sabinsa founder Dr. Muhammed Majeed. “Out of necessity, Sabinsa has earned a reputation for strong enforcement of our intellectual property rights, and will continue to pursue all available legal remedies to protect those rights when necessary.”
“We are very proud of our partnership with Sabinsa to make sure that its patents are enforced and respected in the industry, especially given the investment the company has made in creating and protecting its intellectual property rights,” added James H. Hulme, Sabinsa’s patent counsel. “Sabinsa can now claim a string of patent victories after this latest judgment,” Mr. Hulme said.